Literature DB >> 456408

The protein binding of methotrexate by the serum of normal subjects.

W H Steele, J R Lawrence, J F Stuart, C A McNeill.   

Abstract

The protein binding of methotrexate by serum from eight normal volunteers was assessed by continuous ultrafiltration at pH 7.4 and 37 degrees C. Methotrexate concentrations were measured by radioimmunoassay and the data analysed by the method of Scatchard. The major binding protein was albumin which bound 87.3% of the drug in serum. Analysis of the Scatchard plots indicated two distinct groups of binding sites. Class I was found to have 0.16 +/- 0.05 (S D) binding sites with an intrinsic association constant of 71.15 +/- 35.98 (S D) X 10(4) M-1: Class II had 2.01 +/- 0.93 (S D) binding sites and and affinity of 0.18 +/- 0.15 X 10(4) M-1. No great change in the percentage of methotrexate bound occurred until the total concentration of the drug exceeded 50 muMol 1-1.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 456408     DOI: 10.1007/bf00558441

Source DB:  PubMed          Journal:  Eur J Clin Pharmacol        ISSN: 0031-6970            Impact factor:   2.953


  21 in total

1.  Simple model to explain effects of plasma protein binding and tissue binding on calculated volumes of distribution, apparent elimination rate constants and clearances.

Authors:  J G Wagner
Journal:  Eur J Clin Pharmacol       Date:  1976       Impact factor: 2.953

Review 2.  Cytokinetics and chemotherapy of psoriasis.

Authors:  G D Weinstein; J L McCullough
Journal:  J Invest Dermatol       Date:  1976-07       Impact factor: 8.551

3.  Improved therapeutic index of methotrexate with "leucovorin rescue".

Authors:  M Levitt; M B Mosher; R C DeConti; L R Farber; R T Skeel; J C Marsh; M S Mitchell; R J Papac; E D Thomas; J R Bertino
Journal:  Cancer Res       Date:  1973-07       Impact factor: 12.701

4.  Effectiveness of high-dose infusions of methotrexate followed by leucovorin in carcinoma of the head and neck.

Authors:  M S Mitchell; N W Wawro; R C DeConti; S R Kaplan; R Papac; J R Bertino
Journal:  Cancer Res       Date:  1968-06       Impact factor: 12.701

5.  Recent advances in the chemotherapy of metastatic osteogenic sarcoma.

Authors:  N Jaffe
Journal:  Cancer       Date:  1972-12       Impact factor: 6.860

6.  The effect of organic acids on renal clearance of methotrexate in man.

Authors:  D G Liegler; E S Henderson; M A Hahn; V T Oliverio
Journal:  Clin Pharmacol Ther       Date:  1969 Nov-Dec       Impact factor: 6.875

7.  Methotrexate megadosage followed by folate rescue. I. A study in clearance patterns.

Authors:  S Salasoo; M G Irving; R Lam-Po0Tang; D O'Gorman-Hughes; A Freedman
Journal:  Med J Aust       Date:  1976-05-22       Impact factor: 7.738

Review 8.  High-dose methotrexate with folinic acid rescue.

Authors:  J F Bender; W R Grove; C L Fortner
Journal:  Am J Hosp Pharm       Date:  1977-09

9.  Evaluation of methotrexate in the treatment of bronchogenic carcinoma.

Authors:  R G Vincent; J W Pickren; T B Fergen; H Takita
Journal:  Cancer       Date:  1975-09       Impact factor: 6.860

10.  Comparison of three radioligands, selenium-75, lodine-125, and tritium, in the radioimmunoassay of methotrexate.

Authors:  J W Paxton; F J Rowell; G M Cree
Journal:  Clin Chem       Date:  1978-09       Impact factor: 8.327

View more
  10 in total

Review 1.  Antineoplastic drugs in 1990. A review (Part II).

Authors:  D J Black; R B Livingston
Journal:  Drugs       Date:  1990-05       Impact factor: 9.546

2.  Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate.

Authors:  H Franck; R Rau; G Herborn
Journal:  Clin Rheumatol       Date:  1996-03       Impact factor: 2.980

3.  Dose-dependent disposition of methotrexate in Abcc2 and Abcc3 gene knockout murine models.

Authors:  Zhan Wang; Qingyu Zhou; Gary D Kruh; James M Gallo
Journal:  Drug Metab Dispos       Date:  2011-08-12       Impact factor: 3.922

4.  Extracorporeal Treatment for Methotrexate Poisoning: Systematic Review and Recommendations from the EXTRIP Workgroup.

Authors:  Marc Ghannoum; Darren M Roberts; David S Goldfarb; Jesper Heldrup; Kurt Anseeuw; Tais F Galvao; Thomas D Nolin; Robert S Hoffman; Valery Lavergne; Paul Meyers; Sophie Gosselin; Tudor Botnaru; Karine Mardini; David M Wood
Journal:  Clin J Am Soc Nephrol       Date:  2022-03-02       Impact factor: 10.614

5.  Clearance studies of methotrexate and 7-hydroxy-methotrexate in rabbits after multiple-dose infusion.

Authors:  M L Chen; W L Chiou
Journal:  J Pharmacokinet Biopharm       Date:  1983-10

6.  Melphalan concentration dependent plasma protein binding in healthy humans and rats.

Authors:  N H Greig; D J Sweeney; S I Rapoport
Journal:  Eur J Clin Pharmacol       Date:  1987       Impact factor: 2.953

Review 7.  Clinical pharmacokinetics of commonly used anticancer drugs.

Authors:  F M Balis; J S Holcenberg; W A Bleyer
Journal:  Clin Pharmacokinet       Date:  1983 May-Jun       Impact factor: 6.447

8.  The protein binding of methotrexate in the serum of patients with neoplastic disease.

Authors:  W H Steele; J R Lawrence; J F Stuart; C A McNeill
Journal:  Cancer Chemother Pharmacol       Date:  1981       Impact factor: 3.333

9.  Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate.

Authors:  H Franck; R Rau; G Herborn
Journal:  Clin Rheumatol       Date:  1996-05       Impact factor: 2.980

10.  Pharmacokinetics of different doses of methotrexate at steady state by in situ microdialysis in a rat model.

Authors:  P O Ekstrøm; A Anderson; D J Warren; K E Giercksky; L Slørdal
Journal:  Cancer Chemother Pharmacol       Date:  1995       Impact factor: 3.333

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.